Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • system_architect_enterprise system_architect_enterprise Dec 24, 2012 8:55 AM Flag

    FDA APPROVES! This is GREAT news.

    FDA approval is GREAT news for patients and families dealing with HoFH.

    CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, today announced that the U.S. Food & Drug Administration (FDA) has approved JUXTAPID(TM) (lomitapide) capsules as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non- high-density-lipoprotein cholesterol (non-HDL) in patients with homozygous familial hypercholesterolemia (HoFH).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AEGR
17.66-0.10(-0.56%)Aug 28 4:00 PMEDT